Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded by D. Boral Capital to Buy Rating

Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by equities researchers at D. Boral Capital from a “hold” rating to a “buy” rating in a report released on Monday, MarketBeat reports. The firm presently has a $9.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 144.57% from the stock’s previous close.

Separately, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Trading Up 11.2 %

CTXR stock opened at $3.68 on Monday. Citius Pharmaceuticals has a 52 week low of $2.44 and a 52 week high of $26.75. The company has a market cap of $26.60 million, a P/E ratio of -0.61 and a beta of 1.48. The company’s 50-day moving average price is $5.75 and its 200 day moving average price is $12.12.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in CTXR. Armistice Capital LLC purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at about $5,928,000. Geode Capital Management LLC lifted its stake in Citius Pharmaceuticals by 14.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after buying an additional 232,656 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at approximately $118,000. Wealth Advisory Solutions LLC grew its holdings in Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after buying an additional 50,000 shares during the last quarter. Finally, Arkadios Wealth Advisors increased its position in Citius Pharmaceuticals by 33.3% during the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after buying an additional 50,000 shares in the last quarter. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.